Mechanisms of Disease: HDL metabolism as a target for novel therapies
Daniel J Rader
Correspondence Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, 654 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104, USA
Email rader@mail.med.upenn.edu
Despite aggressive lipid-lowering therapy, coronary heart disease event rates remain unacceptably high, indicating the need for additional therapeutic approaches. Notably, low HDL-cholesterol levels remain an independent risk factor for adverse coronary events even in patients with naturally low or therapeutically lowered LDL-cholesterol levels. Here, Daniel Rader examines the current status of the development of novel therapies aimed at raising HDL-cholesterol levels or improving the function of HDL.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
?Orphans? meet cholesterolNature Medicine News and Views (01 Oct 2000)
Heart disease Good cholesterol newsNature News and Views (26 Aug 1999)
RESEARCH
Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategyNature Genetics Letter (01 Sep 1998)
See all 54 matches for Research